Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models
- Joseph P. Steiner*†,
- Gregory S. Hamilton‡,
- Douglas T. Ross*,
- Heather L. Valentine*,
- Hongzhi Guo*,
- Maureen A. Connolly*,
- Shi Liang*,
- Cynthia Ramsey*,
- Jia-He J. Li‡,
- Wei Huang‡,
- Pamela Howorth*,
- Rajat Soni*,
- Michael Fuller*,
- Hans Sauer*,
- Alison C. Nowotnik*, and
- Peter D. Suzdak*
Although immunosuppressant immunophilin ligands promote neurite outgrowth in vitro, their neurotrophic activities are clearly independent of their immunosuppressive activity. In the present report, a novel nonimmunosuppressive immunophilin ligand, GPI-1046 (3-(3-pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate) is described. In vitro, GPI-1046 bound to FK506 binding protein-12 and elicited neurite outgrowth from sensory neuronal cultures with picomolar potency with maximal effects comparable to nerve growth factor. In vivo, GPI-1046 stimulated the regeneration of lesioned sciatic nerve axons and myelin levels. In the central nervous system, GPI-1046 promoted protection and/or sprouting of serotonin-containing nerve fibers in somatosensory cortex following parachloroamphetamine treatment. GPI-1046 also induced regenerative sprouting from spared nigrostriatal dopaminergic neurons following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice or 6-hydroxydopamine (6-OHDA) toxicity in rats. The rotational abnormality in 6-OHDA treated rats was alleviated by GPI-1046. These neurotrophic actions in multiple models suggest therapeutic utility for GPI-1046 in neurodegenerative diseases.
Footnotes
-
↵ To whom reprint requests should be addressed.
-
Solomon Snyder, Johns Hopkins University School of Medicine, Baltimore, MD
ABBREVIATIONS
- GPI-1046,
- 3-(3-pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate;
- MPTP,
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
- 6-OHDA,
- 6-hydroxy dopamine;
- TH,
- tyrosine hydroxylase;
- PCA,
- parachloroamphetamine;
- FKBP,
- FK506 binding protein;
- GAP-43,
- growth-associated protein of 43 kDa
- Received December 1, 1996.
- Accepted December 23, 1996.
- Copyright © 1997, The National Academy of Sciences of the USA



